AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24818542 — intervention group
Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 258
Study 22268817 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapydan (7% lidocaine and 7% tetracaine)
Number of subjects: 100
Study 22268817 — intervention group
Group type: COMPARATOR
Intervention: Ametop (4% tetracaine)
Number of subjects: 100
Study 22268817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 21170697 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg EPs 7630 daily
Number of subjects: 406
Study 21170697 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg EPs 7630 daily
Number of subjects: 406
Study 21170697 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg EPs 7630 daily
Number of subjects: 406
Study 21170697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 17191265 — intervention group
Group type: COMPARATOR
Intervention: Standard olanzapine tablets
Number of subjects: 38
Study 17191265 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating olanzapine
Number of subjects: 38
Study 15718656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Knee Sleeve
Number of subjects: 0
Study 12005078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent CRM197 pneumococcal conjugate vaccine (PCV)
Number of subjects: 37868
Study 9807847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 80
Study 9807847 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 80
Study 9807847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Isoflurane anesthesia
Number of subjects: 80
Study 7659241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost, technician-administered anxiety reduction intervention (removing heart rate feedback, cognitive distraction, controlled breathing techniques)
Number of subjects: 0
Study 2747301 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone family assessment intervention
Number of subjects: 224
Study 57448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment for five years
Number of subjects: 63
Study 57448 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 63
Study 57448 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed onset of oestrogen treatment (3 to 6 years)
Number of subjects: 63
Study 57448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 63
Study 57448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 63
Study 31035474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato Nutrient Complex (TNC) 15 mg lycopene
Number of subjects: 0
Study 31035474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato Nutrient Complex (TNC) 30 mg lycopene
Number of subjects: 0
Study 31035474 — intervention group
Group type: COMPARATOR
Intervention: Tomato Nutrient Complex (TNC) 5 mg lycopene
Number of subjects: 0
Study 31035474 — intervention group
Group type: COMPARATOR
Intervention: Synthetic lycopene 15 mg
Number of subjects: 0
Study 28590377 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace intervention with a thoracolumbosacral orthosis (TLSO)
Number of subjects: 168
Study 26688484 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 67
Study 26688484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23863812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg and Valsartan 160 mg
Number of subjects: 48
Study 23863812 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg and placebo
Number of subjects: 48
Study 23863812 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg and placebo
Number of subjects: 48
Study 21592232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg daily for 12 weeks
Number of subjects: 56
Study 21592232 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5mg daily for 12 weeks
Number of subjects: 56
Study 19628740 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon AcrySof Natural intraocular lens (ANIOL)
Number of subjects: 42
Study 19628740 — intervention group
Group type: COMPARATOR
Intervention: Alcon AcrySof three‐piece acrylic intraocular lens (AIOL)
Number of subjects: 42
Study 19628740 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of L
Number of subjects: 42
Study 19628740 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of Z
Number of subjects: 42
Study 17019636 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation
Number of subjects: 200
Study 17019636 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation including repeat procedures
Number of subjects: 200
Study 17019636 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation in paroxysmal AF patients considered optimal candidates
Number of subjects: 200
Study 17019636 — intervention group
Group type: EXPERIMENTAL
Intervention: Major complications
Number of subjects: 200
Study 12807578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise (EX) program
Number of subjects: 20
Study 12807578 — intervention group
Group type: COMPARATOR
Intervention: Recreational therapy (C)
Number of subjects: 20
Study 10969220 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization of salbutamol (15 mg during the first hour and 12.5 mg over the next 5 hours)
Number of subjects: 42
Study 10969220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nebulization of salbutamol (5 mg every 20 minutes during the first hour and 2.5 mg hourly over the next 5 hours)
Number of subjects: 42
Study 10969220 — intervention group
Group type: COMPARATOR
Intervention: Both groups (continuous and intermittent nebulization)
Number of subjects: 42
Study 8796387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PaO2 (approximately 50 mmHg) Low PEEP (approximately 1 cmH2O)
Number of subjects: 13
Study 8796387 — intervention group
Group type: EXPERIMENTAL
Intervention: High PaO2 (approximately 80 mmHg) High PEEP (approximately 10 cmH2O)
Number of subjects: 13
Study 8796387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PaO2 (approximately 50 mmHg) High PEEP (approximately 10 cmH2O)
Number of subjects: 13
Study 8796387 — intervention group
Group type: EXPERIMENTAL
Intervention: High PaO2 (approximately 80 mmHg) Low PEEP (approximately 1 cmH2O)
Number of subjects: 13
Study 1535588 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (E)
Number of subjects: 13
Study 1535588 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (D) and Glyceroltrinitrate (G)
Number of subjects: 13
Study 6387965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg
Number of subjects: 12
Study 6387965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg + Sotalol (STL) 320 mg
Number of subjects: 12
Study 6387965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30264419 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation therapy
Number of subjects: 21
Study 30264419 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help therapy
Number of subjects: 21
Study 31074652 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mM ascorbic acid (AA) during the HS diet
Number of subjects: 29
Study 31074652 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µM apocynin during the HS diet
Number of subjects: 29
Study 31074652 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µM Tempol during the HS diet
Number of subjects: 29
Study 31074652 — intervention group
Group type: COMPARATOR
Intervention: High-sodium diet (HS)
Number of subjects: 29
Study 31074652 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (LS)
Number of subjects: 29
Study 28306481 — intervention group
Group type: EXPERIMENTAL
Intervention: Health message video about mortality risk to smokers
Number of subjects: 999
Study 28306481 — intervention group
Group type: COMPARATOR
Intervention: Control video on a health topic unrelated to smoking
Number of subjects: 999
Study 25465111 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 1644
Study 25465111 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 1644
Study 23352379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg daily
Number of subjects: 129
Study 23352379 — intervention group
Group type: COMPARATOR
Intervention: Glipizide (initiated with 2.5 mg daily, titrated up to 10 mg twice daily)
Number of subjects: 129
Study 23352379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 129
Study 23352379 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 129
Study 21402328 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming console exercise
Number of subjects: 19
Study 21402328 — intervention group
Group type: COMPARATOR
Intervention: Treadmill or cycle ergometer exercise
Number of subjects: 19
Study 18548148 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in daily sodium intake of 1840 mg/day
Number of subjects: 11550
Study 18548148 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in dietary sodium from 1200 mg/day to 2400 mg/day
Number of subjects: 11550
Study 16570051 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000‐20,000 IU three times weekly plus best standard treatment (BST)
Number of subjects: 182
Study 16570051 — intervention group
Group type: COMPARATOR
Intervention: Best standard treatment (BST) only
Number of subjects: 182
Study 12755663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day)
Number of subjects: 270
Study 12755663 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics, olanzapine, risperidone
Number of subjects: 270
Study 11761770 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU of retinyl palmitate and 30 mg of beta-carotene daily during pregnancy; 200,000 IU of retinyl palmitate at delivery
Number of subjects: 312
Study 11761770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 9436685 — intervention group
Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 32
Study 9436685 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist
Number of subjects: 32
Study 8219523 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz TENS
Number of subjects: 72
Study 8219523 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz TENS
Number of subjects: 72
Study 8219523 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 Hz TENS
Number of subjects: 72
Study 8219523 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 72
Study 3301783 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 38
Study 3301783 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 38
Study 29316450 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism training intervention
Number of subjects: 61
Study 29316450 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched educational control
Number of subjects: 61
Study 27341812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM™) plus Usual Care (UC)
Number of subjects: 750
Study 27341812 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) alone
Number of subjects: 750
Study 24603902 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS)
Number of subjects: 166
Study 24603902 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 166
Study 24603902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EBUS/EUS
Number of subjects: 166
Study 24603902 — intervention group
Group type: COMPARATOR
Intervention: Surgical mediastinal staging (SMS)
Number of subjects: 166
Study 24603902 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography
Number of subjects: 166
Study 23183528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 100 mg + PegIFN/RBV
Number of subjects: 64
Study 23183528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 200 mg + PegIFN/RBV
Number of subjects: 64
Study 23183528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg + PegIFN/RBV
Number of subjects: 64
Study 23183528 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PegIFN/RBV
Number of subjects: 64
Study 22151909 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND programme (theory driven group structured education)
Number of subjects: 178
Study 22151909 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 178
Study 18076588 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% FFS
Number of subjects: 344
Study 18076588 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 5% FFS
Number of subjects: 344
Study 18076588 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 10% FFS
Number of subjects: 344
Study 18076588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 16928600 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily
Number of subjects: 12
Study 16928600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14603503 — intervention group
Group type: EXPERIMENTAL
Intervention: Coground product (1:2:3 DHEA-α-Cd-glycine)
Number of subjects: 0
Study 14603503 — intervention group
Group type: COMPARATOR
Intervention: Untreated drug
Number of subjects: 0
Study 10710409 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of ferrous sulfate (S) per day for 6 weeks
Number of subjects: 42
Study 10710409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 42
Study 9173524 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast sonography (HyCoSy) with Echovist 200
Number of subjects: 50
Study 9173524 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 50
Study 9173524 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient discomfort assessment
Number of subjects: 50
Study 8229720 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.03% flurbiprofen sodium
Number of subjects: 120
Study 8229720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3101821 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory health worker visits (monthly by a respiratory nurse)
Number of subjects: 75
Study 3101821 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visits)
Number of subjects: 75
Study 30428094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay-cataract group (small aperture corneal inlay implanted in non-dominant eye)
Number of subjects: 16
Study 30428094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay-cataract group
Number of subjects: 16
Study 30428094 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional cataract surgery in both eyes)
Number of subjects: 16
Study 30428094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 27592092 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe renal dysfunction (GFR ≤30 mL/min)
Number of subjects: 2531
Study 27592092 — intervention group
Group type: COMPARATOR
Intervention: Moderate renal dysfunction (GFR 31 to 60 mL/min)
Number of subjects: 2531
Study 27592092 — intervention group
Group type: COMPARATOR
Intervention: None/mild renal dysfunction (GFR >60 mL/min)
Number of subjects: 2531
Study 24015965 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Sealed (WS) pedometer group
Number of subjects: 123
Study 24015965 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsealed (US) pedometer group
Number of subjects: 123
Study 24015965 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Sealed (DS) pedometer group
Number of subjects: 123
Study 22349735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers met the goal for TV/video viewing (<1 h/day)
Number of subjects: 428
Study 22349735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers met the goal for sugar-sweetened beverage intake (<1 serving/day)
Number of subjects: 428
Study 22349735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers met the goal for fast food intake (<1 time/week)
Number of subjects: 428
Study 15994720 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 63
Study 15994720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gradual substitution)
Number of subjects: 63
Study 12427650 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (90 microg/kg)
Number of subjects: 16
Study 12427650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12427650 — intervention group
Group type: COMPARATOR
Intervention: Placebo and rFVIIa
Number of subjects: 16
Study 9715340 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual problem-solving treatment
Number of subjects: 0
Study 9715340 — intervention group
Group type: EXPERIMENTAL
Intervention: Group educational programme
Number of subjects: 0
Study 9715340 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7657860 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session AIDS education lecture
Number of subjects: 838
Study 7657860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lecture)
Number of subjects: 838
Study 2467983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride (0.375, 0.75, 1.5, 3 and 6 mg)
Number of subjects: 5
Study 2467983 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.1 and 0.2 mg)
Number of subjects: 5
Study 2467983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone hydrochloride (4 and 8 mg)
Number of subjects: 5
Study 2467983 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 322672 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpipramine 3 X 50 mg per day for 8 weeks
Number of subjects: 30
Study 322672 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase for 3 weeks
Number of subjects: 30
Study 322672 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 30
Study 30367519 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (2,120 mg eicosapentaenoic acid/600 mg docosohexaenoic acid)
Number of subjects: 24
Study 30367519 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study 28290162 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2032
Study 28290162 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 2032
Study 24934401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100
Study 24934401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23151431 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term androgen suppression (STAS) with leuprorelin (22.5 mg every 3 months)
Number of subjects: 1071
Study 23151431 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-term androgen suppression (ITAS) with leuprorelin (22.5 mg every 3 months)
Number of subjects: 1071
Study 23151431 — intervention group
Group type: EXPERIMENTAL
Intervention: ITAS plus zoledronic acid (4 mg every 3 months)
Number of subjects: 1071
Study 23151431 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy boost
Number of subjects: 1071
Study 20089074 — intervention group
Group type: EXPERIMENTAL
Intervention: RTP-ASE Qontrast-generated images (A, beta, Axbeta) during adenosine stress
Number of subjects: 67
Study 20089074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined A, beta and Axbeta image interpretation
Number of subjects: 67
Study 20089074 — intervention group
Group type: COMPARATOR
Intervention: SPECT (99mTc-tetrofosmin)
Number of subjects: 67
Study 18545204 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (25-g supplement)
Number of subjects: 60
Study 18545204 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (100 kcal and 250 kcal)
Number of subjects: 60
Study 18545204 — intervention group
Group type: COMPARATOR
Intervention: Energy-free placebo
Number of subjects: 60
Study 16190917 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg donepezil daily for 4 weeks
Number of subjects: 11
Study 16190917 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg donepezil daily for 8 weeks
Number of subjects: 11
Study 16190917 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal, untreated controls)
Number of subjects: 11
Study 16190917 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-drug discontinuation
Number of subjects: 11
Study 12135946 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 7
Study 12135946 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 7
Study 12135946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11757256 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depression group
Number of subjects: 81
Study 11757256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysthymia group
Number of subjects: 81
Study 11757256 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory group
Number of subjects: 81
Study 11757256 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sad mood state group
Number of subjects: 81
Study 11757256 — intervention group
Group type: COMPARATOR
Intervention: Normal-control group
Number of subjects: 81
Study 7777104 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy without iron supplementation (Group 3)
Number of subjects: 40
Study 7777104 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy with iron supplementation (Group 4)
Number of subjects: 40
Study 7777104 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (Group 2)
Number of subjects: 40
Study 7777104 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 40
Study 2111979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate delivered via face mask and spacer device (infants)
Number of subjects: 16